OR WAIT 15 SECS
The acquisition expands Eurofins Genomics’ gene portfolio while bolstering Blue Heron’s production capabilities.
In an Aug. 6, 2019 press release, Eurofins Genomics announced the completion of its acquisition of Blue Heron Biotech, a Bothell, WA-based gene synthesis company. The deal will bolster Blue Heron's production capabilities while expanding Eurofins Genomics’ gene portfolio into cloning and complex gene constructs. The acquisition will also strengthen Eurofins Genomics’ product portfolio in the synthetic biology market.
The companies share similar main product segments-oligonucleotides, sequencing, and synthetic genes. Eurofins Genomics’ product offerings include oligonucleotide synthesis, Sanger sequencing, next-generation sequencing, and gene synthesis. With the acquisition, the company can now provide holistic solutions to customers, including regulatory coverage for its products-ISO 13485, ISO 9001, CLIA, CAP, GLP, and FDA compliance for the manufacturing of cGMP oligonucleotides used in analyte specific reagent and in-vitro diagnostic products for the clinical industry.
Source: Eurofins Genomics